Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk: The Market Doesn't Get It
10:55am, Friday, 11'th Jul 2025
Novo Nordisk remains dominant in diabetes and obesity care, with strong growth and expanding market share despite recent investor concerns. The company's pipeline, especially the oral GLP-1 and Alzhei
Smart Money Going in Senior Health: Key Stocks in Elderly Care
10:50am, Friday, 11'th Jul 2025
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Novo Nordisk (NVO) Beats Stock Market Upswing: What Investors Need to Know
06:46pm, Thursday, 10'th Jul 2025
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $71.01, denoting a +1.89% move from the preceding trading day.
3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies
08:17am, Thursday, 10'th Jul 2025
I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. Three companies—Pfizer, BMW, and Singapore Airlines—currentl
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly
06:16pm, Wednesday, 09'th Jul 2025
Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong with when investing in for the long term. They are leaders in the GLP-1 weigh
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
12:50pm, Wednesday, 09'th Jul 2025
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
Novo Nordisk's Canadian drug patent lapses, opening market for Hims & Her Health
11:50am, Wednesday, 09'th Jul 2025
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth company, among others, will now be allowed to make exact copies of Novo's
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
09:00am, Wednesday, 09'th Jul 2025
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Novo Nordisk: Reclaiming Market Share
03:56am, Wednesday, 09'th Jul 2025
Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects due to rising global demand and a robust pipeline. Recent stock weakness is overdone; valuation models s
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Hims & Hers Health Inc. to Contact Law Firm
03:19pm, Tuesday, 08'th Jul 2025
NEW YORK , July 8, 2025 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Hims & Hers Health, Inc. (NYSE: HIMS) Sha
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
10:41am, Tuesday, 08'th Jul 2025
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval
09:32am, Tuesday, 08'th Jul 2025
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving
Novo Nordisk: Obesity war heating up, but Danish giant can still be a winner
07:16am, Tuesday, 08'th Jul 2025
Novo Nordisk (NYSE:NVO) is losing ground in Europe's red-hot market for weight-loss and diabetes drugs. Its rival, Eli Lilly and Co (NYSE:LLY) is racing ahead, and investors are taking notice.
2 S&P 500 Dividend Stocks That Could Climb 17% or More, According to Wall Street
04:57am, Tuesday, 08'th Jul 2025
Image source: Getty Images.
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
11:19am, Monday, 07'th Jul 2025
Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company's stock has plummeted approximately 18% over the past month, reflecting recen
